GlassScriptPhysician profile
Suzanne La Lande
NPI 1114477833
$2,426.77
in general payments reported to CMS, 2019-2025
23 companies · $617 in 2025
The $617 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $52.82 · 2022: $389 · 2023: $684 · 2024: $685 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,789 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,789.42 |
| Education | $195.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $638.09 | 2021-2025 | Myrbetriq, Xtandi |
| Abbvie INC. | $300.82 | 2022-2025 | |
| Teleflex LLC | $232.88 | 2024 | Urolift |
| Boston Scientific Corporation | $176.42 | 2025 | Spaceoar Vue System - 10ml, Rezum Generator, Moses |
| Janssen Biotech, INC. | $142.80 | 2022-2025 | Erleada |
| Merck Sharp & Dohme LLC | $110.90 | 2025 | Keytruda |
| 180 Medical, INC. | $101.22 | 2022-2024 | Cure Catheter |
| Sumitomo Pharma America, INC. | $94.34 | 2023-2025 | Gemtesa |
| Myriad Genetic Laboratories, INC. | $89.82 | 2022-2025 | Prolaris, Myrisk |
| Astrazeneca Pharmaceuticals LP | $88.17 | 2023-2024 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $76.02 | 2023-2025 | |
| Tolmar, INC. | $71.46 | 2025 | Eligard, Jatenzo |
| Endo Pharmaceuticals INC. | $68.75 | 2022-2023 | Xiaflex, Aveed |
| Pfizer INC. | $57.89 | 2022-2024 | |
| Amgen INC. | $34.25 | 2022-2023 | Xgeva |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $26.13 | 2022 | |
| Dendreon Pharmaceuticals LLC | $25.89 | 2022 | |
| Immunitybio, INC. | $19.29 | 2024 | |
| Urogen Pharma, INC. | $19.03 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.88 | 2023 | Oxlumo |
| Endo USA, INC. | $17.40 | 2025 | Aveed, Xiaflex |
| Ambu INC. | $12.50 | 2022 | |
| Travere Therapeutics, INC. | $3.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne La Lande listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.